期刊文献+

重症肌无力患者的运动康复及药学监护 被引量:3

Pharmaceutical Care and Exercise Rehabilitation in Patients with Myasthenia Gravis
下载PDF
导出
摘要 目的:通过对1例重症肌无力患者的药学监护进行分析与探讨,为临床用药提供有价值的参考信息,为更多重症肌无力患者出院后的康复训练及护理用药提供指导。方法:回顾性分析1例重症肌无力患者的药学监护情况,评估药物治疗方案,做出不良反应警示,对患者进行有效的康复护理指导及用药教育。结果:患者经过治疗病情好转,肌张力恢复良好,经过康复训练基本恢复生活能力。结论:合理的康复指导及药学监护可以显著降低患者出现不良反应的风险,改善重症肌无力的治疗效果,提高患者出院后生活质量。 Object: According to analysis and investigations, clinical pharmacist will make improvement in prescribing and provide instructions for nursing and drug-usage in inpatients and discharged patients. Methods: The medical surveillance of 1 patient with myasthenia gravis was retrospectively analyzed, and the drug treatment plan was evaluated. Clinical pharmacist need make warnings of adverse reactions and conduct drug education and rehabilitation guidance for patients. Results: The patient's muscle tension recovered well and basically restoring the ability to live. After a return visit, the condition was well controlled and no obvious adverse reactions occurred. Conclusions: The risk of adverse reactions in patients will be decrease and treatment effect of myasthenia gravis patients will be increased with the help of pharmaceutical care. The recovery rate and quality of life of discharged patients is improved because of the guidance of sports pharmacists in rehabilitation.
作者 张濛 Zhang Meng(Shanxi Medical University,Taiyuan Shanxi 030002,China)
机构地区 山西医科大学
出处 《武术研究》 2018年第6期154-156,共3页 Wushu Studies
关键词 重症肌无力 运动康复 药学监护 用药教育 Myasthenia gravis Exercise rehabilitation Pharmaceutical care Medication education
  • 相关文献

参考文献5

二级参考文献43

  • 1丁力.氨基糖甙类抗生素与锂在神经肌肉节头的相互作用[J].国外医药(抗生素分册),1994,15(5):366-367. 被引量:3
  • 2张志国,芮军,杨世英,黎新建.重症肌无力27例的外科治疗[J].四川医学,2007,28(4):408-409. 被引量:2
  • 3中国成人血脂异常防治指南[J].中华心血管病杂志,2007,35(5):390-419. 被引量:5223
  • 4[1]Xu L, Villain M, Galin FS, et al. Prevention and reversal of experimental autoimmune myasthenia gravis by a monoclonal antibody against acetylcholine receptor-specific T cells. Cell Immunol, 2001, 208(2): 107-114.
  • 5[3]Lennon VA. Experimental autoimmune myasthenia: a model of myasthenia gravis in rats and guinea pigs. J Exp Med,1975,141:1365.
  • 6[5]Howard JF. Adverse drug effects on neuromuscular transmission. Semin Neurol,1990,10(1):89-102.
  • 7[6]Christadoss P,Poussin M,Deng C. Animal models of myasthenia gravis[J]. Clin Immunol, 2000,94(2):75-87.
  • 8Xu L, Villain M, Galin F S, et al. Prevention and reversal of experimental autoimmune myasthenia gravis by a monoclonal antibody against acetylcholine receptor-specific T cells[J]. Cell Immunol, 2001, 208(2): 107-114.
  • 9Cadisch R, Streit E, Hartmann K. Exacerbation of Pseudoparalytic myasthenia gravis following azithromycin (Zithromax)[J]. Schweiz Med Wochenschr, 1996, 126(8): 308-310.
  • 10Vial T, Chauplannaz G, Brunel P, et al. Exacerbation of myasthenia gravis by pefloxacin[J]. Rev neurol (Paris), 1995, 151(4): 286-287.

共引文献23

同被引文献9

引证文献3

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部